Compare Ascendis Pharma A/S (ASND) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Roundhill NVDA WeeklyPay ETF — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Roundhill NVDA WeeklyPay ETF trades at $36.6. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| ASND | NVDW | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $53.42 |
52-Week Low | $163.32 | $31.88 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NVDW trades at $37.56, up 4.71% today, but technical indicators signal bearish momentum with selling pressure outweighing buying signals. The stock faces resistance near $38-39 while finding support around $35-33. Recent dividend activity shows frequent but variable payouts, with Seeking Alpha noting the ETF's quasi-synthetic leveraged position in Nvidia generates fluctuating income streams.
The outlook remains cautious due to technical bearish signals and payout volatility. Investment opportunity exists for income-focused investors seeking Nvidia exposure, but risks include dependency on NVDA performance and significant weekly dividend fluctuations that challenge yield predictability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
